Tonix Pharmaceuticals Enrolls First Patient in Phase 2 HORIZON Study of TNX-102 SL for MDD

With first-patient enrollment now confirmed in the HORIZON study, Tonix Pharmaceuticals is pressing its already-approved sublingual cyclobenzaprine formulation into a second clinical indication, a move that will sharpen CMC and manufacturing scale-up scrutiny for a dose form that carries its own GMP complexity.

HORIZON is a 6-week, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as first-line monotherapy in adults with major depressive disorder. Approximately 360 participants will be enrolled across roughly 30 U.S. sites. The primary endpoint is change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6; secondary endpoints cover global impression scores, anxiety ratings, and sleep quality measures.

TNX-102 SL was approved by the FDA in August 2025 and launched commercially as TONMYA® for fibromyalgia in adults. The rationale for the MDD extension centers on the compound's mechanism: potent antagonism at four neuronal receptors implicated in sleep architecture, specifically deep slow-wave sleep, which the company positions as a driver of neuro-restoration in stress-associated conditions. Prior Phase 2 PTSD and Phase 3 fibromyalgia data generated signals for improvement in both depressive symptoms and subjective sleep quality, forming the evidentiary basis for HORIZON.

For manufacturing and quality teams, the operational read is material. Sublingual tablet formulations require tightly controlled disintegration profiles, transmucosal absorption consistency, and moisture-sensitive packaging, each a validated process parameter under 21 CFR Part 211 and ICH Q10 quality system expectations. Expanding an approved sublingual product into a new indication at Phase 2 scale does not reset those validated parameters, but it does introduce site-transfer and batch-record scrutiny if commercial supply is drawn from the same line supporting TONMYA®. Any process changes made to accommodate MDD trial supply would require comparability assessment against the approved fibromyalgia product.

The MDD market context adds regulatory weight: more than 21 million U.S. adults experience a major depressive episode annually, and tolerability-driven discontinuation remains a documented gap in existing antidepressant classes. A first-line monotherapy claim, if supported by HORIZON data, would require a labeling package that distinguishes TNX-102 SL's sleep-targeting mechanism from established serotonergic and noradrenergic agents, a differentiation argument that regulatory affairs leads will need to build well before any NDA submission.

The six-week MADRS readout from HORIZON will serve as the first controlled signal test for TNX-102 SL in MDD and will determine whether Tonix advances toward a potentially pivotal program in this indication.

Source: Tonix Pharmaceuticals via GlobeNewswire, June 29, 2026.